gmp
gmp

Find Clinical Drug Pipeline Developments & Deals by F. Hoffmann-La Roche

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AAV vectors based gene therapies

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

            Recipient: Dyno Therapeutics

            Deal Size: $1,800.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement October 14, 2020

            Details:

            Dyno will design novel AAV capsids with improved functional properties for gene therapy, while Roche and Spark Therapeutics will be conducting preclinical, clinical and commercialization activities for gene therapy product candidates using the novel capsids.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ETD002

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ETD002

            Highest Development Status: Phase I Product Type: Small molecule

            Recipient: Enterprise Therapeutics

            Deal Size: Undisclosed Upfront Cash: $96.8 milion

            Deal Type: Acquisition October 07, 2020

            Details:

            Enterprise Therapeutics' TMEM16A portfolio includes ETD002, first of its compounds to hit clinical stage. In pre-clinical models the compound has been found to enhances the activity of TMEM16A.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Engineered Antibodies

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Argenx BVBA

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership October 06, 2020

            Details:

            Argenx and Chugai have entered into a research license and option agreement under which argenx may access Chugai’s SMART-Ig® and ACT-Ig®.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VB10.NEO

            Therapeutic Area: Oncology Product Name: VB10.NEO

            Highest Development Status: Phase II Product Type: Vaccine

            Recipient: Vaccibody

            Deal Size: $715.0 million Upfront Cash: $200.0 million

            Deal Type: Licensing Agreement October 01, 2020

            Details:

            The agreements aims to develop and commercialize DNA-based individualized neoantigen vaccines for the treatment of cancers. Vaccibody will conduct development through the end of Phase 1b and Genentech will be responsible for development and commercialization thereafter.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Atezolizumab,Bevacizumab

            Therapeutic Area: Oncology Product Name: Tecentriq

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 25, 2020

            Details:

            Chugai has obtained approval for an additional indication of Tecentriq® Intravenous Infusion 1200 mg and Avastin® Intravenous Infusion 100 mg/4 mL and 400 mg/16 mL for the treatment of unresectable hepatocellular carcinoma from the Ministry of Health, Labour and Welfare.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Polatuzumab Vedotin,Bendamustine,Rituximab

            Therapeutic Area: Oncology Product Name: Polivy

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 24, 2020

            Details:

            Health Canada has granted market authorization to Polivy™(polatuzumab vedotin), in combination with bendamustine and rituximab (BR) for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Inzomelid

            Therapeutic Area: Neurology Product Name: IZD174

            Highest Development Status: Phase I Product Type: Small molecule

            Recipient: Inflazome

            Deal Size: Undisclosed Upfront Cash: $441.9 million

            Deal Type: Acquisition September 21, 2020

            Details:

            The acquisition gives Roche full rights to Inflazome’s entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Recipient: Scenic Biotech

            Deal Size: $375.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration September 21, 2020

            Details:

            Under the terms of the agreement, Scenic will utilize its Cell-Seq platform and its data warehouse of genetic modifiers to identify drug targets in multiple therapeutic areas.